3-[7,12,18-Tris(2-carboxyethyl)-3,8,13,17-tetramethyl-21,22-dihydroporphyrin-2-yl]propanoic acid;dihydrochloride | 14643-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四吡咯及其衍生物
• 英文名称: 3-[7,12,18-Tris(2-carboxyethyl)-3,8,13,17-tetramethyl-21,22-dihydroporphyrin-2-yl]propanoic acid;dihydrochloride
• 英文别名: 3-[7,12,18-tris(2-carboxyethyl)-3,8,13,17-tetramethyl-21,22-dihydroporphyrin-2-yl]propanoic acid;dihydrochloride
• CAS: 14643-66-4；68938-73-8
• 化学式: C36H40Cl2N4O8
• 分子量: 727.6
• InChiKey: OWYQJTWIRYHERL-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMSO（轻微，超声处理），甲醇（轻微）
• 沸点：
  1258.0±65.0 °C(Predicted)
• 密度：
  1.366±0.06 g/cm3(Predicted)

制备方法与用途

生物活性

Coproporphyrin III (Zincphyrin) 是一种天然存在的卟啉衍生物，主要存在于尿液中。

靶点

Human Endogenous Metabolite

体外研究

Coproporphyrin III methyl ester is repeatedly isolated in considerable amount from both feces and urine. A great increase of coproporphyrin III excretion is unaccompanied by symptoms or signs of porphyria, metal or chemical poisoning or liver disease. Primary cultures of chick embryo hepatocytes have been used to study the mechanism by which chemicals cause accumulation of intermediates of the heme synthetic pathway. In the presence of the porphyrin precursor, 5-aminolevulinate (ALA), addition of insulin causes a striking increase in accumulation of uroporphyrin I and coproporphyrin III. Antioxidants abolishes the uroporphyrin I accumulation and increases coproporphyrin III.

体内研究

Urinary DMA and porphyrin profile can be used as an early warning biomarker for chronic MMA exposure before the onset of cancer. After 4 weeks the level of coproporphyrin III concentration significantly increases in all the treatment groups compared to the control.